CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial
Exuma Biotechnology will expand its program to multiple centers in China this summer and decide whether to expand to the US or Europe by the end of the year, the company's founder said. It has also developed its own electronic system for ensuring chain of custody for its products.